China Universal Asset Management Co. Ltd. Purchases 8,427 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

China Universal Asset Management Co. Ltd. raised its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 351.6% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 10,824 shares of the biotechnology company's stock after purchasing an additional 8,427 shares during the period. China Universal Asset Management Co. Ltd.'s holdings in Sarepta Therapeutics were worth $1,044,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Vanguard Group Inc. grew its holdings in shares of Sarepta Therapeutics by 0.5% during the third quarter. Vanguard Group Inc. now owns 8,572,944 shares of the biotechnology company's stock valued at $1,039,212,000 after buying an additional 41,465 shares during the last quarter. Wellington Management Group LLP grew its holdings in shares of Sarepta Therapeutics by 1.4% during the third quarter. Wellington Management Group LLP now owns 3,909,800 shares of the biotechnology company's stock valued at $473,946,000 after buying an additional 54,698 shares during the last quarter. State Street Corp grew its holdings in shares of Sarepta Therapeutics by 7.9% during the second quarter. State Street Corp now owns 1,913,732 shares of the biotechnology company's stock valued at $219,161,000 after buying an additional 139,756 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Sarepta Therapeutics by 3.5% during the first quarter. Geode Capital Management LLC now owns 1,261,971 shares of the biotechnology company's stock valued at $173,938,000 after buying an additional 43,239 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of Sarepta Therapeutics by 40.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,171,442 shares of the biotechnology company's stock valued at $161,461,000 after buying an additional 334,749 shares during the last quarter. Institutional investors own 86.68% of the company's stock.

Sarepta Therapeutics Stock Performance

SRPT traded up $0.29 during trading on Friday, hitting $126.08. The company's stock had a trading volume of 303,501 shares, compared to its average volume of 1,047,135. The company has a quick ratio of 3.45, a current ratio of 3.95 and a debt-to-equity ratio of 1.32. Sarepta Therapeutics, Inc. has a one year low of $55.25 and a one year high of $159.89. The firm has a market cap of $11.84 billion, a PE ratio of -20.60 and a beta of 0.94. The business's 50 day simple moving average is $126.97 and its 200-day simple moving average is $110.31.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported $0.47 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.50. The business had revenue of $396.80 million for the quarter, compared to the consensus estimate of $387.18 million. Sarepta Therapeutics had a negative net margin of 43.11% and a negative return on equity of 18.97%. The company's quarterly revenue was up 53.6% on a year-over-year basis. During the same period last year, the firm earned ($1.24) earnings per share. As a group, sell-side analysts predict that Sarepta Therapeutics, Inc. will post 1.94 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on SRPT shares. Needham & Company LLC cut their price target on shares of Sarepta Therapeutics from $169.00 to $166.00 and set a "buy" rating on the stock in a report on Thursday, February 29th. Evercore ISI increased their price target on shares of Sarepta Therapeutics from $108.00 to $138.00 and gave the company an "in-line" rating in a report on Tuesday, February 20th. UBS Group raised their target price on shares of Sarepta Therapeutics from $164.00 to $167.00 and gave the stock a "buy" rating in a report on Friday, March 1st. BMO Capital Markets began coverage on shares of Sarepta Therapeutics in a report on Wednesday, January 31st. They issued an "outperform" rating and a $170.00 target price on the stock. Finally, Deutsche Bank Aktiengesellschaft began coverage on shares of Sarepta Therapeutics in a report on Tuesday, December 12th. They issued a "buy" rating and a $109.00 target price on the stock. Four analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Sarepta Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $158.38.

Insider Activity

In other news, Director Kathryn Jean Boor sold 761 shares of the firm's stock in a transaction on Monday, March 11th. The shares were sold at an average price of $122.93, for a total transaction of $93,549.73. Following the sale, the director now directly owns 7,516 shares in the company, valued at approximately $923,941.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Kathryn Jean Boor sold 761 shares of the firm's stock in a transaction on Monday, March 11th. The shares were sold at an average price of $122.93, for a total transaction of $93,549.73. Following the sale, the director now directly owns 7,516 shares in the company, valued at approximately $923,941.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Bilal Arif sold 2,000 shares of the firm's stock in a transaction on Friday, March 1st. The shares were sold at an average price of $128.84, for a total transaction of $257,680.00. Following the sale, the insider now owns 26,836 shares in the company, valued at $3,457,550.24. The disclosure for this sale can be found here. Insiders have sold 22,096 shares of company stock worth $2,739,419 in the last three months. Company insiders own 7.40% of the company's stock.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.